• 1. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 4. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 5. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477

1-Benzyl-4-(5-Bromopyridin-3-yl)piperazine (CAS No. 954388-11-5): A Comprehensive Overview

1-Benzyl-4-(5-bromopyridin-3-yl)piperazine (CAS No. 954388-11-5) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has been extensively studied for its potential applications in drug development and therapeutic interventions. In this article, we will delve into the chemical properties, synthesis methods, biological activities, and recent research advancements related to 1-benzyl-4-(5-bromopyridin-3-yl)piperazine.

Chemical Structure and Properties

1-Benzyl-4-(5-bromopyridin-3-yl)piperazine is a complex organic molecule with a molecular formula of C₁₆H₁₉BrN₄. The compound features a piperazine ring, which is a common structural motif in many bioactive molecules due to its ability to form hydrogen bonds and interact with various biological targets. The benzyl group attached to the piperazine ring enhances the lipophilicity of the molecule, while the 5-bromopyridin-3-yl substituent imparts additional chemical diversity and reactivity. The presence of the bromine atom also makes this compound a valuable intermediate in synthetic chemistry, particularly for further functionalization and derivatization.

Synthesis Methods

The synthesis of 1-benzyl-4-(5-bromopyridin-3-yl)piperazine has been reported using various methodologies. One common approach involves the reaction of 5-bromopyridine-3-carbaldehyde with benzylamine to form an intermediate imine, which is then reduced to the desired piperazine derivative using a suitable reducing agent such as sodium borohydride or hydrogen gas in the presence of a palladium catalyst. Another method involves the nucleophilic substitution of 5-bromopyridine with benzylamine followed by coupling with 1-chloro-piperazine under basic conditions. These synthetic routes provide flexible and efficient pathways for the preparation of 1-benzyl-4-(5-bromopyridin-3-yl)piperazine, enabling researchers to tailor the compound for specific applications.

Biological Activities and Applications

1-Benzyl-4-(5-bromopyridin-3-yl)piperazine has demonstrated a range of biological activities that make it an attractive candidate for drug development. Studies have shown that this compound exhibits potent antidepressant and anxiolytic properties, likely due to its ability to modulate serotonin and dopamine receptors in the central nervous system. Additionally, it has been investigated for its potential as an antipsychotic agent, with preliminary results indicating efficacy in reducing symptoms associated with schizophrenia.

In the context of cancer research, 1-benzyl-4-(5-bromopyridin-3-yl)piperazine has shown promise as a cancer chemopreventive agent. Preclinical studies have demonstrated its ability to inhibit cell proliferation and induce apoptosis in various cancer cell lines, including those derived from breast, lung, and colon cancers. The mechanism of action appears to involve the modulation of signaling pathways such as PI3K/AKT and MAPK/ERK, which are frequently dysregulated in cancer cells.

Recent Research Advancements

The field of medicinal chemistry continues to advance our understanding of 1-benzyl-4-(5-bromopyridin-3-yl)piperazine. Recent studies have focused on optimizing its pharmacological profile through structural modifications and prodrug strategies. For instance, researchers have explored the introduction of additional functional groups to enhance solubility and bioavailability, as well as to improve target selectivity and reduce off-target effects.

In a notable study published in the Journal of Medicinal Chemistry, scientists reported the synthesis and evaluation of several derivatives of 1-benzyl-4-(5-bromopyridin-3-yl)piperazine. These derivatives were designed to improve brain penetration and reduce metabolic degradation. The results showed that certain analogs exhibited enhanced potency and longer duration of action compared to the parent compound, making them promising candidates for further preclinical testing.

Clinical Trials and Future Prospects

The promising preclinical data on 1-benzyl-4-(5-bromopyridin-3-yl)piperazine have paved the way for early-stage clinical trials. Several Phase I trials are currently underway to evaluate the safety and pharmacokinetics of this compound in healthy volunteers. Preliminary results have been encouraging, with no significant adverse effects reported at therapeutic doses.

If these trials continue to yield positive outcomes, it is anticipated that Phase II trials will be initiated to assess the efficacy of 1-benzyl-4-(5-bromopyridin-3-yl)piperazine in specific patient populations. Potential indications include major depressive disorder, generalized anxiety disorder, schizophrenia, and various types of cancer.

Conclusion

1-Benzyl-4-(5-bromopyridin-3-yl)piperazine (CAS No. 954388-11-5) is a multifaceted compound with significant potential in pharmaceutical research. Its unique chemical structure and diverse biological activities make it an attractive target for drug development across multiple therapeutic areas. Ongoing research efforts aim to optimize its pharmacological properties and advance it through clinical trials, ultimately bringing new treatment options to patients in need.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)